These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 25086050)
21. Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Bergmann F; Zacher A; Nass A; Urban R; Werner C; Spevakné-Göröcs T; Kungel M; Ebrecht M; Modell S Pharmacopsychiatry; 2009 May; 42(3):101-8. PubMed ID: 19452378 [TBL] [Abstract][Full Text] [Related]
23. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. Takeuchi Y; Shinozaki T; Matsuyama Y BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575 [TBL] [Abstract][Full Text] [Related]
24. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Gagne JJ; Wang SV; Rassen JA; Schneeweiss S Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):619-27. PubMed ID: 24788694 [TBL] [Abstract][Full Text] [Related]
25. Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. Hallas J; Pottegård A; Wang S; Schneeweiss S; Gagne JJ Am J Epidemiol; 2016 Nov; 184(10):761-769. PubMed ID: 27780801 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Ott E; Nussmeier NA; Duke PC; Feneck RO; Alston RP; Snabes MC; Hubbard RC; Hsu PH; Saidman LJ; Mangano DT; ; J Thorac Cardiovasc Surg; 2003 Jun; 125(6):1481-92. PubMed ID: 12830070 [TBL] [Abstract][Full Text] [Related]
28. Postmarketing surveillance methodologies. Edlavitch SA Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280 [TBL] [Abstract][Full Text] [Related]
29. Telithromycin and acute liver failure. Graham DJ N Engl J Med; 2006 Nov; 355(21):2260-1. PubMed ID: 17124030 [No Abstract] [Full Text] [Related]
30. Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. Montastruc F; Nie R; Loo S; Rej S; Dell'Aniello S; Micallef J; Suissa S; Renoux C JAMA Psychiatry; 2019 Apr; 76(4):409-417. PubMed ID: 30698607 [TBL] [Abstract][Full Text] [Related]
31. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723 [TBL] [Abstract][Full Text] [Related]
32. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review. Gault N; Castañeda-Sanabria J; De Rycke Y; Guillo S; Foulon S; Tubach F BMC Med Res Methodol; 2017 Feb; 17(1):25. PubMed ID: 28178924 [TBL] [Abstract][Full Text] [Related]
33. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Chen LC; Ashcroft DM Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957 [TBL] [Abstract][Full Text] [Related]
35. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Schug SA; Joshi GP; Camu F; Pan S; Cheung R Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866 [TBL] [Abstract][Full Text] [Related]
37. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Layton D; Wilton LV; Shakir SA Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327 [TBL] [Abstract][Full Text] [Related]
38. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. Etminan M; Gill S; Fitzgerald M; Samii A J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278 [TBL] [Abstract][Full Text] [Related]
39. New methodological approaches were able to effectively reduce immeasurable time bias in case-only designs. Jeong HE; Oh IS; Lee H; Filion KB; Shin JY J Clin Epidemiol; 2021 Mar; 131():1-10. PubMed ID: 33171274 [TBL] [Abstract][Full Text] [Related]
40. A novel weighting method to remove bias from within-subject exposure dependency in case-crossover studies. Kubota K; Kelly TL; Sato T; Pratt N; Roughead E; Yamaguchi T BMC Med Res Methodol; 2021 Oct; 21(1):214. PubMed ID: 34657592 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]